Comparison of clinicopathological features present at initial diagnosis and at relapse in HIV+MCD
| . | First diagnosis . | First relapse (no lymphoma) . | P value . |
|---|---|---|---|
| Mean age, y (range) | 42 (21-69) | 44 (31-59) | MW: .83 |
| Male sex | 72/84 (86%) | 12/13 (92%) | FET: 1.0 |
| Ethnicity | |||
| Black African | 26 (31%) | 5/13 (38%) | |
| White | 56 (67%) | 8/13 (62%) | |
| Other | 2 (2%) | 0/13 (0%) | |
| On cART | 41/84 (49%) | 13/13 (100%) | FET: .0004 |
| Mean time on cART, y (range) | 1.9 (0-16) | 4.6 (0.2-9.6) | MW: .0018 |
| Mean CD4 (range) | 283 cells/mL (24-834) | 536 cells /mL (79-1457) | MW: .026 |
| Mean CD4% (range) | 17% (2-35) | 20% (10-33) | MW: .16 |
| Mean CD8 (range) | 912 cells/mL (164-2558) | 1340 cells/mL (279-3570) | MW: .060 |
| Mean CD8% (range) | 55% (25-83) | 52% (32-79) | MW: .29 |
| Mean CD19 (range) | 272 cells/mL (8-1508) | 474 cells /mL (55-1451) | MW: .28 |
| Mean CD19% (range) | 16% (0.2-53) | 15% (4-33) | MW: .77 |
| Mean NK (range) | 87 cells/mL (4-493) | 184 cells /mL (32-772) | MW: .050 |
| Mean NK% (range) | 5% (0.4-29) | 6% (2-15) | MW: .49 |
| VL undetectable | 27/83 (33%) | 6/13 (46%) | FET: .36 |
| VL <400 copies/mL | 45/83 (54%) | 12/13 (92%) | FET: .013 |
| Median duration of symptoms, mo (range) | 3 (1-48) | 2 (1-4) | MW: .036 |
| ECOG >1 | 42/84 (50%) | 5/13 (38%) | FET: .56 |
| Median plasma HHV8 (range) | 237 200 copies/mL (200-554 000 000) | 177 500 copies/mL (19 800-23 000 000) | MW: .61 |
| . | First diagnosis . | First relapse (no lymphoma) . | P value . |
|---|---|---|---|
| Mean age, y (range) | 42 (21-69) | 44 (31-59) | MW: .83 |
| Male sex | 72/84 (86%) | 12/13 (92%) | FET: 1.0 |
| Ethnicity | |||
| Black African | 26 (31%) | 5/13 (38%) | |
| White | 56 (67%) | 8/13 (62%) | |
| Other | 2 (2%) | 0/13 (0%) | |
| On cART | 41/84 (49%) | 13/13 (100%) | FET: .0004 |
| Mean time on cART, y (range) | 1.9 (0-16) | 4.6 (0.2-9.6) | MW: .0018 |
| Mean CD4 (range) | 283 cells/mL (24-834) | 536 cells /mL (79-1457) | MW: .026 |
| Mean CD4% (range) | 17% (2-35) | 20% (10-33) | MW: .16 |
| Mean CD8 (range) | 912 cells/mL (164-2558) | 1340 cells/mL (279-3570) | MW: .060 |
| Mean CD8% (range) | 55% (25-83) | 52% (32-79) | MW: .29 |
| Mean CD19 (range) | 272 cells/mL (8-1508) | 474 cells /mL (55-1451) | MW: .28 |
| Mean CD19% (range) | 16% (0.2-53) | 15% (4-33) | MW: .77 |
| Mean NK (range) | 87 cells/mL (4-493) | 184 cells /mL (32-772) | MW: .050 |
| Mean NK% (range) | 5% (0.4-29) | 6% (2-15) | MW: .49 |
| VL undetectable | 27/83 (33%) | 6/13 (46%) | FET: .36 |
| VL <400 copies/mL | 45/83 (54%) | 12/13 (92%) | FET: .013 |
| Median duration of symptoms, mo (range) | 3 (1-48) | 2 (1-4) | MW: .036 |
| ECOG >1 | 42/84 (50%) | 5/13 (38%) | FET: .56 |
| Median plasma HHV8 (range) | 237 200 copies/mL (200-554 000 000) | 177 500 copies/mL (19 800-23 000 000) | MW: .61 |
FET, Fisher's exact test; MW, Mann-Whitney test; VL, plasma HIV RNA viral load.